亞虹醫藥(688176.SH):在2024年美國臨牀腫瘤學會泌尿生殖系統腫瘤研討會上發佈APL-1706用於膀胱癌診斷的臨牀試驗數據
格隆匯1月28日丨亞虹醫藥(688176.SH)公佈,公司APL-1706用於膀胱癌診斷的多中心臨牀試驗(以下簡稱“本研究”)結果入選2024年美國臨牀腫瘤學會泌尿生殖系統腫瘤研討會(ASCOGU),並以壁報的形式發佈III期臨牀試驗數據和真實世界研究數據。
APL-1706是目前全球唯一獲批的輔助膀胱癌診斷或手術的顯影劑類藥物,通過與藍光膀胱鏡的聯合使用可以有效提高膀胱癌的檢出率(尤其是原位癌(CIS)的檢出率),使手術切除更完全,從而降低腫瘤複發率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.